You are here: Industry Insights > COVID-19 vaccine

News List

Novavax gets EC marketing authorization for Covid-19 vaccine By PBR Staff Writer Pharmaceutical-Business-Review
December 22, 2021
Developed using Novavax’ recombinant nanoparticle technology, the vaccine also known as NVX-CoV2373 is a protein-based Covid-19 vaccine candidate which is engineered from the genetic sequence of the initial SARS-CoV-2 virus strain.
European Commission grants conditional marketing authorization for Novavax COVID-19 vaccine WorldPharmaNews
December 21, 2021
Novavax, Inc. (Nasdaq: NVAX), a biotechnology company dedicated to developing and commercializing next-generation vaccines for serious infectious diseases, today announced that the European Commission (EC)...
Novavax Receives Positive European Medicines Agency Recommendation for Conditional Marketing Authorization of its COVID-19 Vaccine prnewswire
December 21, 2021
Novavax, Inc. (Nasdaq: NVAX), a biotechnology company dedicated to developing and commercializing next-generation vaccines for serious infectious diseases, today announced that the European Medicines Agency (EMA)...
Moderna says booster dose of its COVID-19 vaccine appears protective against Omicron expresspharma
December 21, 2021
The company still plans to develop a vaccine specifically to protect against Omicron, which it hopes to advance into clinical trials early next year
Novavax’s COVID-19 vaccine highly effective in preventing disease EuropeanPharmaceuticalReview
December 20, 2021
Recently published data suggests Novavax’s investigational COVID-19 vaccine, NVX-CoV2373, is 90 percent effective at preventing COVID-19 illness and 100 percent effective at preventing moderate-to-severe symptoms.
Vaxart to Test Cross-Reactivity of its COVID-19 Oral Tablet Vaccine Against Omicron AmericanPharmaceuticalReview
December 17, 2021
Vaxart, Inc. plans to test the cross-reactivity of its oral tablet COVID-19 vaccine candidate against the Omicron SARS-CoV-2 variant in two different studies expected to begin next month.
SQREEM's New AI-powered Study Examines Motivations Surrounding COVID-19 Vaccine Resistance in the US prnasia
December 17, 2021
COVID-19 vaccines have once again become a hot topic in the United States as President Joe Biden pushes on with vaccination mandates in a bid to manage concerns around the Omicron variant ahead of the winter flu season.
Novavax Announces Submission of New Drug Application in Japan for Approval of COVID-19 Vaccine prnasia
December 17, 2021
Novavax, Inc. (Nasdaq: NVAX), a biotechnology company dedicated to developing and commercializing next-generation vaccines for serious infectious diseases, today announced the submission of a New Drug Application (NDA)...
CDC Panel Advises That Other Vaccines Be Preferred Over J&J Shot Drugs
December 17, 2021
Following continued reports of a rare but life-threatening clotting condition linked to the Johnson & Johnson coronavirus vaccine, a federal advisory panel on Thursday recommended that the Pfizer/BioNTech...
Moderna COVID-19 Vaccine Effective 5 Months After Second Dose AmericanPharmaceuticalReview
December 16, 2021
Kaiser Permanente research in Southern California published Nov. 25, 2021, in The Lancet Regional Health – Americas confirmed high Moderna COVID-19 vaccine effectiveness up to 5 months after the second dose. Effectiveness was 87% against COVID-19 ...

Previous page 1 2 3 4 5 6 7 8 9 10 ... 116 117 Next page